Study demonstrates farm-to-fork benefits of immunological estrus suppression in market gilts
A new study reveals that market gilts grow better and produce more meat that is more palatable to consumers when treated with a vaccine that temporarily delays puberty.
27 August 2020
3 minute read
By: 
| References | ||||
|---|---|---|---|---|
| 1 Nautrup BP, Van Vlaenderen I, Mah CK. | ||||
| “The effect of immunization against gonadotropin-releasing factor in market gilts: Meta-analyses of parameters relevant for pig producers, pork packers and retailers/consumers.”. Res Vet Sci 2019, | ||||
| 2 | ||||
| The compound is classified as a vaccine in all major swine markets except the US, where it is registered as a pharmaceutical. | ||||
| 3 | ||||
| GnRF analog-diptheria toxoid conjugate is currently licensed for use in gilts in Canada, US, Spain, Thailand and several Central and South American countries. | ||||
| 4 Poulsen, et al. | ||||
| “The effect of immunization against gonadotropin-releasing factor on growth performance, carcass characteristics and boar taint relevant to pig producers and the pork packing industry: A meta-analysis.”. Res Vet Sci. | 119:182-195. |
